What is Cardeas Pharma?
Cardeas Pharma is a biopharmaceutical company focused on addressing the critical unmet medical needs posed by highly antibiotic-resistant organisms in hospital-acquired respiratory infections. The company leverages novel formulations of established antibiotics combined with advanced drug delivery technology to create effective treatments for patients in the critical-care setting. This strategic focus positions Cardeas Pharma at the forefront of combating challenging infectious diseases.
How much funding has Cardeas Pharma raised?
Cardeas Pharma has raised a total of $41.5M across 2 funding rounds:
Series A
$7.5M
Series B
$34M
Series A (2012): $7.5M, investors not publicly disclosed
Series B (2013): $34M led by Devon Park Bioventures, Avalon Ventures, Washington Research Foundation, Novo A/S, Delphi Ventures, and H.I.G. BioVentures, LLC
Key Investors in Cardeas Pharma
Devon Park Bioventures
Devon Park Bioventures is a venture capital firm specializing in early-stage investments, likely focusing on innovative healthcare and biotechnology companies with significant market potential.
Novo A/S
Novo Holdings is a Danish investment company with a strong focus on the life sciences sector, particularly in pharmaceuticals and biotechnology, indicating a strategic interest in Cardeas Pharma's therapeutic area.
H.I.G. BioVentures, LLC
H.I.G. BioVentures is a venture capital arm of H.I.G. Capital, dedicated to investing in growth-stage healthcare and biotechnology companies, suggesting a focus on companies with scalable solutions and strong clinical pipelines.
What's next for Cardeas Pharma?
The substantial enterprise-level funding indicates Cardeas Pharma is in a robust growth phase, likely preparing for late-stage clinical trials, regulatory submissions, and eventual commercialization. The recent strategic investment suggests strong confidence from backers in the company's therapeutic approach and market potential. Future endeavors will likely involve scaling manufacturing capabilities, expanding the clinical development team, and forging strategic partnerships to accelerate market access for its innovative inhaled antibiotic therapies.
See full Cardeas Pharma company page
